In recent molecular docking studies, Tomoo Iwakuma’s group identified DNAJA1 inhibitors, PLTFBH and A11, which reduced DNAJA1 levels and then induced conformational mutp53 degradation, thereby inhibiting cancer cell migration [103,104]. The gene discussed is DNAJA1; the disease is cancer.